Takotsubo cardiomyopathy in the setting of COVID-19

  • Received 14.12.2020

  • Revised 15.01.2021

  • Accepted 23.02.2021



  • 1,053 Views

  • Retrieved from Volume 3, No. 1, 2021

  • Pages 133-138

Summary. It is anticipated that as the number of COVID-19 cases rises worldwide, there will be an increase in the number of associated cardiovascular complications, and Takotsubo syndrome is one of them. Clinicians should be aware of the diversity of cardiovascular complications and should strategize appropriately for diagnosing and mana­ging them. The aim of the study – to analyze the literature on the features of Takotsubo syndrome in COVID-19 pandemic. Materials and Methods. The study looked at scientific publications over the last decade that  are available on the Internet, with the keywords “Stress cardiomyopathy”, “Takotsubo syndrome”,  “COVID-19″. Results. As COVID-19 pandemic progresses globally, a clear picture of cardiovascular manifestation and associated complications is emerging. The reports in the literature illustrate various cardiovascular complications of COVID-19 infection, including acute myocardial infarction, myocarditis, cardiomyopathy, arrhythmias and venous thromboembolism. Information on Takotsubo cardiomyopathy as a complication of COVID-19 is based on the results of studies with relatively limited number of case reports and case series. Patients with COVID-19 have  been shown to have elevated levels of  proinflammatory cytokines. The cytokine storm brought about by overwhelming systemic COVID-19 disease can be the physical and chemical stressor. Furthermore, studies also reported an increased incidence of development of stress cardiomyopathy due to COVID-19 pandemic in COVID-19-negative patients suggesting a key role for psychological distress in its development. Conclusions. The correlation between the  SARS-CoV-2 virus pandemic and the development of stress cardiomyopathy is undeniable. In some cases, it is a cardiac manifestation of infectious disease is triggered by Coronavirus SARS-CoV-2, in other situations it is the result of increased anxiety and stress due to COVID-19 pandemic

stress cardiomyopathy, Takotsubo syndrome, COVID-19, SARS-COV-2

https://doi.org/10.11603/bmbr.2706-6290.2021.1.12099

[1] Oryshchyn   ND,   Ivaniv   YA   [Cardiovascular complications  in  COVID-19:  case  report  and  concise review].  Proc  Shevchenko  Sci  Soc  Med  Sci.  2020;62(2): 87-98. Ukrainian.

[2] Suspitsyna IN, Sukmanova IA [Takotsubo syndrome. Clinical and pathogenetic aspects. Basics of diagnosis and treatment]. Kardiologiya. 2020;60(2): 96-103. Russian.

[]3 Shlyakhto EV, Parmon EV, Berngardt ER, Zhabina ES [Features  of  electrocardiographic  changes  in  non-coronarogenic syndromes in patients with COVID-19]. Ros Card J. 2020;25(7): 194-00. Russian.

[4] Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ et al. International Expert Consensus Document on Takotsubo  Syndrome  (Part  I):  Clinical  Characteristics, Diagnostic Criteria, and Pathophysiology. European Heart Journal. 2018;39(22): 2032-46.

[5] Schultz T, Shao Y, Redfors B, Bergmann Sverrisdóttir Y, Råmunddal  T,  Albertsson  P  et  al.  Stress-Induced Cardiomyopathy in Sweden: Evidence for Different Ethnic Predisposition  and  Altered  Cardio-Circulatory  Status. Cardiology. 2012;122(3): 180-6.

[6] Wittstein IS. Stress cardiomyopathy: A syndrome of catecholamine mediated myocardial stunning? Cellular and Molecular Neurobiology. 2012;32(5): 847-57.

[7] Redfors  B,  Vedad  R,  Angerås  O,  Råmunddal  T, Petursson  P,  Haraldsson  I  et  al.  Mortality  in  takotsubo syndrome  is  similar  to  mortality  in  myocardial  infarction — A report from the SWEDEHEART registry. International Journal of Cardiology. 2015;185: 282-9.

[8] Madias  JE.  Why  the  current  diagnostic  criteria  of Takotsubo  syndrome  are  outmoded:  A  proposal  for  new criteria.  International  Journal  of  Cardiology.  2014;174(3): 468-70.

[9] Parodi G, Citro R, Bellandi B, Provenza G, Marrani M, Bossone E. Revised clinical diagnostic criteria for Tako-tsubo syndrome: The Takotsubo Italian Network proposal. International Journal of Cardiology. 2014;172(1): 282-3.

[10] Prasad A, Dangas G, Srinivasan M, Yu J, Gersh BJ, Mehran R et al. Incidence and angiographic characteristics of patients with apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the    HORIZONS-AMI trial: An analysis from  a  multicenter,  international  study  of  ST-elevation myocardial  infarction.  Catheterization  and Cardiovascular Interventions. 2014;83(3): 343-8.

[11] Lyon AR,  Bossone  E,  Schneider  B,  Sechtem  U, Citro R, Underwood SR et al. Current state of knowledge on  Takotsubo  syndrome:  a  Position  Statement  from  the Taskforce  on  Takotsubo  syndrome  of the  Heart  Failure Association of the European Society of Cardiology: Current state  of  knowledge  on  Takotsubo  syndrome.  European Journal of Heart Failure. 2016;18(1): 8-27.

[12] Aizawa  K,  Suzuki  T.  Takotsubo  Cardiomyopathy: Japanese  perspective.  Heart  Failure  Clinics.  2013;9(2): 243-7.

[13] Staedtke  V,  Bai  R-Y,  Kim  K,  Darvas  M,  Davila ML,  Riggins  GJ,  et  al.  Disruption  of  a  self-amplifying catecholamine  loop  reduces  cytokine  release  syndrome. Nature. 2018;564: 273-7.

[14] Shilova  AS,  Shmotkina  AO,  Yafarova  AA, Gilyarov MYu [Takotsubo syndrome: Contemporary views on the pathogenesis, prevalence and prognosis]. Rats far-makot v kardiol. 2018;14(4): 598-04. Russian

[15] Husam  M  Salah, Jawahar  L  Mehta  Takotsubo cardiomyopathy and COVID-19 infection. European Heart Journal – Cardiovascular Imaging. 2020;21: 1299-300.

[16] Gomez J, Nair G, Nanavaty P, Rao A, Marinescu K, Suboc T. COVID-19-associated takotsubo cardiomyopathy BMJ Case Rep 2020;13: 236-40.

[17] Delmas C, Lairez O, Mulin E, Delmas T, Boudou N,Dumonteil  N,  Biendel-Picquet  C, Roncalli  J, Elbaz  M,Galinier M, Carrié D. Anxiodepressive disorders and chronic psychological  stress  are  associated  with  Tako-Tsubo cardiomyopathy – new physiopathological hypothesis. Circ. J. 2013;77: 175-80.

[18] Jabri A, Kalra A, Kumar A, et al., Incidence of stress  cardiomyopathy  during  the  coronavirus  disease 2019  pandemic,  JAMA  Network  Open.  2020;3(7); e2014780.

[19] Giavarini A, Chedid A, Bobrie G, Plouin P-F, Hagège A, Amar L. Acute catecholamine cardiomyopathy in patients with  phaeochromocytoma  or  functional  paraganglioma. Heart. 2013;99(19): 1438-44.

[20] Finsterer  J,  Wahbi  K.  CNS  disease  triggering Takotsubo stress cardiomyopathy. International Journal of Cardiology. 2014;177(2): 322-9.

[21] Suzuki  H,  Matsumoto  Y,  Kaneta  T,  Sugimura  K, Takahashi J, Fukumoto Y et al. Evidence for Brain Activation in  Patients  with  Takotsubo  Cardiomyopathy.  Circulation Journal. 2014;78: 256-8.

[22] Martens G, Gerritsen L, Duijndam S, Salemink E, Engelhard  I,  et  al.  Fear  of  Corona  Virus  (COVID-19): predictors in an online study conducted in March 2020, J. Anxiety  Disord.  Available  from: https://doi.org/10.1016/j.janxdis.2020.102258.

[23] Meyer P, Degrauwe S, Van Delden C, et al. Typical takotsubo syndrome triggered by SARSCoV-2 infection. Eur Heart J. 2020;41(19): 1860.

[24] Minhas  A,  Scheel  P,  Garibaldi  B.  Takotsubo syndrome  in  the  setting  of  COVID-19.  JACC  Case  Rep. 2020. 2(9): 1321-5.

[25] Ghadri  J,  Wittstein  I,  Prasad  A.  International expert  consensus  document  on  Takotsubo  syndrome (part  I):  clinical  characteristics,  diagnostic  criteria,  and pathophysiology. Eur Heart J. 2018;39(22): 2032-46.

[26] Desai HD, Sharma K, Jadeja DM, Desai HM, Moliya P. COVID-19 pandemic induced stress cardiomyopathy: a literature review. Int J Cardiol Heart Vasc. 2020;31: 100628.

[27] Penefsky  ZJ,  Kahn  M.  Inotropic  effects  of  dexa-methasone in mammalian heart muscle. Eur J Pharmacol. 1971;15:259-66.